首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL4 |
| Uniprot No | P13236 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-92aa |
| 氨基酸序列 | APMGSDPPTACCFSYTARKLPRNFVVDYYETSSLCSQPAVVFQTKRGKQV CADPSESWVQEYVYDLELN |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL4重组蛋白的3篇参考文献示例(内容为模拟生成，非真实文献)：
---
1. **标题**: *Expression and Functional Characterization of Recombinant CCL4/MIP-1β in Escherichia coli*
**作者**: Zhang L, et al.
**摘要**: 本研究报道了在大肠杆菌系统中高效表达重组CCL4蛋白的优化方法，通过亲和层析纯化获得高纯度蛋白，并验证其趋化活性(对THP-1单核细胞的迁移实验)，为后续炎症研究提供可靠工具。
2. **标题**: *Recombinant CCL4 Enhances HIV Infection by Promoting Viral Entry into CD4+ T Cells*
**作者**: Thompson R, et al.
**摘要**: 通过哺乳动物细胞表达系统制备重组CCL4.发现其与CCR5受体结合后显著增强HIV-1对CD4+ T细胞的感染效率，揭示了CCL4在病毒传播中的潜在作用机制。
3. **标题**: *Structural Analysis of Recombinant Human CCL4 and Its Interaction with Glycosaminoglycans*
**作者**: Müller S, et al.
**摘要**: 利用HEK293细胞表达重组人CCL4.结合X射线晶体学解析其三维结构，并证明其与硫酸乙酰肝素的结合能力，为趋化因子与细胞外基质相互作用的调控提供结构基础。
---
注：以上文献信息为示例，实际引用请通过学术数据库(如PubMed、Web of Science)检索真实发表的研究。
**Background of Recombinant CCL4 Protein**
Recombinant CCL4 (C-C motif chemokine ligand 4), also known as macrophage inflammatory protein-1β (MIP-1β), is a small chemokine protein encoded by the *CCL4* gene in humans. It belongs to the CC chemokine subfamily, which plays critical roles in immune regulation, inflammation, and cell recruitment. Naturally produced by immune cells (e.g., T cells, monocytes, and dendritic cells), CCL4 binds to chemokine receptors such as CCR5 and CCR8. mediating leukocyte migration to sites of infection or injury. Its functions extend to modulating immune responses, including T cell activation, dendritic cell maturation, and antiviral defense.
Recombinant CCL4 is engineered in vitro using expression systems (e.g., *E. coli* or mammalian cells) to ensure high purity and bioactivity. This synthetic form retains the native protein’s structural and functional properties, enabling researchers to study its mechanisms without interference from contaminants. Its production typically involves cloning the *CCL4* gene into a vector, transfection into host cells, and purification via chromatography.
In research, recombinant CCL4 is widely used to explore its role in diseases. For instance, it is implicated in HIV pathogenesis due to CCR5 interactions, cancer progression (via tumor microenvironment modulation), and autoimmune disorders like rheumatoid arthritis. It also serves as a tool in drug development, helping identify inhibitors targeting chemokine-receptor pathways. Additionally, recombinant CCL4 aids in studying leukocyte trafficking dynamics in vitro or in animal models.
Despite its therapeutic potential, challenges remain in balancing its pro-inflammatory benefits against risks of excessive immune activation. Current studies focus on optimizing its application in immunotherapy and regenerative medicine while minimizing off-target effects. Overall, recombinant CCL4 is a vital tool for dissecting immune pathways and advancing targeted therapies.
×
